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mental cost-effectiveness ratio (ICER). The analysis covered 10
years, with a Markov cycle of one day. Costs included medica-
tion, consultations and treatment interventions and additional
costs for attending special education. Quality-adjusted life years
(QALY) were used as effectiveness measures. Outcome proba-
bilities were taken from the medical literature and an expert
panel of ﬁve child psychiatrists and pediatricians. Univariate sen-
sitivity analyses were performed to assess the robustness of the
base case estimate. Multivariate sensitivity analysis was used to
estimate a worst and best case ICER. RESULTS: The incremen-
tal cost-effectiveness ratio of methylphenidate-OROS treatment
compared to IR-methylphenidate in youths with ADHD for
whom treatment with IR-methylphenidate is suboptimal, was
2004 euros per QALY. Total costs after 10 years were 15,739
euros for the IR-methylphenidate pathway and 16,015 euros for
the methylphenidate-OROS pathway. In the univariate sensitiv-
ity analysis, the ICER was sensitive to changes in resource use
and the probability of stopping stimulant treatment in favor of
IR-methylphenidate. An ICER of 0 was reached with a 6.2%
price reduction of methylphenidate-OROS. CONCLUSIONS:
Methylphenidate-OROS is a cost-effective treatment for youths
with ADHD for whom treatment with IR-methylphenidate is
suboptimal. With regard to the cost items evaluated in this analy-
sis, higher medication costs of methylphenidate-OROS were
compensated by savings on resource use, yielding similar 10-year
costs compared to treatment with IR-methylphenidate. Future
cost-effectiveness analyses should retrieve estimations for model
parameters from clinical trials or large databases and include
direct non-medical costs associated with methylphenidate 
treatment.
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OBJECTIVES: To retrospectively evaluate 1-year direct health
care cost (antidepressants, hospital stays, rehabilitation) of
patients with depression based on claims data. METHODS:
Billing data of a German sickness fund with 4.7 million life years
insured were used for the period from 2001 to 2003. Beneﬁcia-
ries were included, if they were covered at least three months by
the health insurance and had either an inpatient or sick leave
diagnosis of depression (ICD 10: F32, F33) or at least two pre-
scriptions of an antidepressant (ATC: N06A*) during this
period. For each patient direct health care cost was derived from
the database for the individual observation period and stan-
dardized subsequently to obtain 1-year cost. RESULTS: Out of
1.54 million beneﬁciaries n = 75.078 fulﬁlled the inclusion cri-
teria (mean age: 48 ± 15 years; 57 % female). Total 1-year cost
of illness amounted to €363 per patient (SD: €1584) as actuar-
ial data. The median reimbursed cost of treating depression
accounted for €31, the maximum was €57,404 p.a. per patient,
representing that the majority of the patients caused relatively
low expenditures and only a small group generated high health
care cost. Stratiﬁcation of total cost shows that inpatient care
due to depression caused higher average cost per patient and year
(212 ± €1479) than antidepressant therapy administered by
ofﬁce-based physicians (93 ± €177) or rehabilitation (54 ± €389).
CONCLUSION: The study conﬁrms that hospitalization is the
main cost driver of depression. This is in line with current liter-
ature. There is also evidence that adequate antidepressant treat-
ment prevents from hospital stays. Though, the ﬁndings reveal a
distinct imbalance between inpatient and outpatient cost, espe-
cially for antidepressant pharmacotherapy. Keeping patients in
an ambulatory care setting, supported by an optimized pharma-
cotherapy, might contribute to reduced overall health care spend-
ing per patient.
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OBJECTIVES: It is suggested that full remission should be the
primary goal of depression treatment. However, few previous
studies have directly measured the impact of remission on eco-
nomic disease burden. The aims of this study were to compare
costs of patients in remission with patients not achieving remis-
sion after an episode of major depressive disorder (MDD) in a
Swedish primary care setting, and to determine effect of remis-
sion on overall cost of illness. METHODS: The cost of illness in
remitters and non-remitters was estimated based on of a natu-
ralistic longitudinal survey (HEADIS—Health Economic Aspects
of Depression in Sweden). Records from 447 patients with a
mean follow-up of 6 months were collected from 56 primary care
centre, and the resource use was analyzed for patients having at
least one follow-up visit. Unit costs were derived from standard
Sweden sources. Swedish prevalence estimates were applied to
per patient cost estimates to assess overall burden of illness
among remitters and non-remitters. RESULTS: Full remission
was achieved by 52% of the patients at end of follow-up. For
non-remitters and remitters, total annual per patient costs
amounted to SEK 128,000 and SEK 78,000, respectively. With
MDD prevalence of 5% and Swedish 2005 population exceed-
ing 9 million, overall burden of illness was SEK 46 billion.
Increasing the proportion of remitters by 10% would decrease
an overall burden of illness by 5%, to SEK 44 billion. CON-
CLUSIONS: Remission substantially affects economic burden of
depression, decreasing total per patient cost by almost 40%.
With high prevalence of MDD in Sweden, any strategy that will
increase the remission rate will also markedly reduce the overall
burden of illness. This indicates importance of full remission as
the primary goal of treatment of depression and strengthens evi-
dence that antidepressant treatments leading to rapid remission
may be most beneﬁcial.
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